Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222922 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 138
- Enrollment target
- 17
- Study locations
NCT02222922: Completed Phase 1 study of Neoplasms, sponsored by Pfizer.
NCT02222922 is a Phase 1 study of Neoplasms that has completed, run by Pfizer. The registered enrollment target is 138 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The trial reports 17 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02222922, a Phase 1 study of Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 138 participants
- Enrollment target
- 17
- Study locations
Study Summary
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Primary Outcome
A DLT was any of the following adverse events(AEs) in the first cycle of treatment (within 21 days of first dose or until participant received second infusion if there were treatment delays). (1)Hematologic: including Grade 4 neutropenia lasting \>7 days; Febrile neutropenia; Grade \>=3 neutropenic infection; Grade 4 anemia; Grade \>=3 thrombocytopenia with clinically significant bleeding. (2) Hepatic, including Grade \>=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; alanine am
Conditions Studied
Interventions
- DRUG fluconazole
- DRUG PF-06647020 Q3W
- DRUG PF-06647020 Q2W
- DRUG PF-06647020 combined with Avelumab
Study Locations (17)
Virginia
- Inova Fairfax Hospital Woodburn GYN Infusion Center - Annandale
- Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates (MAGOPSA) - Annandale
- Fairfax Radiological Consultants - Fairfax
- Inova Schar Cancer Institute - Fairfax
- Inova Loudon Hospital - Leesburg
California
- University of California Davis Comprehensive Cancer Center - Sacramento
- University of California Davis Medical Center - Sacramento
- Stanford Cancer Center - Stanford
- Stanford Hospital and Clinics - Stanford
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
Other
- Hospital Universitario Fundacion Jimenez Diaz - Madrid
- Hospital Universitario Madrid Sanchinarro - Madrid
Arizona
- Scottsdale Healthcare Hospitals DBA HonorHealth - Scottsdale
Illinois
- University of Chicago Medicine - Chicago
Michigan
- START Midwest - Grand Rapids
Texas
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2014-10-17 |
| Est. Completion | 2019-11-05 |
| Phase | Phase 1 |
What the finished NCT02222922 record still lists
NCT02222922 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which fluconazole is the first listed.
NCT02222922 lists 17 locations in 8 states (Virginia, California, Alabama).
Frequently Asked Questions
What is clinical trial NCT02222922 about?
NCT02222922 is a clinical study titled "A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors". To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
What is the current status of trial NCT02222922?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2014-10-17. Estimated completion is 2019-11-05.
What conditions does trial NCT02222922 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT02222922?
The interventions under investigation include: fluconazole (DRUG), PF-06647020 Q3W (DRUG), PF-06647020 Q2W (DRUG), PF-06647020 combined with Avelumab (DRUG).
Who is sponsoring clinical trial NCT02222922?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02222922 being conducted?
This trial has 17 study locations across Alabama, Arizona, California, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02222922's enrollment target sits among peer trials
138 61st of 158 higher than 98 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI